Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Midodrine
 | |
| Clinical data | |
|---|---|
| Trade names | Amatine, Gutron, Orvaten, ProAmatine, others |
| Other names | ST-1085; TS-701; 3,6-Dimethoxy-β-hydroxy-N-aminoethanonyl-2-phenylethylamine; 2-Amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 1-2',5'-Dimethoxyphenyl-1)-2 glycinamidoethanol |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a616030 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth[1] |
| Drug class | α1-Adrenergic receptor agonist; Antihypotensive agent; Vasopressor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 93% (as desglymidodrine)[3][4][1] |
| Metabolism | Deglycination[3][1][4] |
| Metabolites | • Desglymidodrine[3][1][4] |
| Onset of action | ≤1 hour[3] |
| Elimination half-life | Midodrine: 0.5 hours[4] Desglymidodrine: 2–4 hours[4][1] |
| Duration of action | 2–6 hours[3][4] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.151.349 100.050.842, 100.151.349 |
| Chemical and physical data | |
| Formula | C12H18N2O4 |
| Molar mass | 254.286 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Midodrine, sold under the brand names ProAmatine and Orvaten among others, is a vasopressor or antihypotensive medication used to treat orthostatic hypotension (low blood pressure when standing) and urinary incontinence.[3][5][1] It is taken by mouth.[3][1]
Side effects of midodrine include hypertension (high blood pressure), paresthesia, itching, goosebumps, chills, urinary urgency, urinary retention, and urinary frequency.[3] Midodrine is a prodrug of its active metabolite desglymidodrine.[3][1] This metabolite acts as a selective agonist of the α1-adrenergic receptor.[3][1] This in turn results in vasoconstriction and increased blood pressure.[3][1]
Midodrine was discovered by 1971[6] and was introduced for medical use in the United States in 1996.[citation needed]
- ^ a b c d e f g h i j Cite error: The named reference
DrugBankwas invoked but never defined (see the help page). - ^ "Proamatine- midodrine hydrochloride tablet". DailyMed. Retrieved 14 August 2021.
- ^ a b c d e f g h i j k "ProAmatine® (midodrine hydrochloride) Tablets" (PDF). fda.gov. Food and Drug Administration. Retrieved 28 August 2024.
- ^ a b c d e f Gilden JL (2004). "Midodrine and Other Sympathomimetics". Primer on the Autonomic Nervous System. Elsevier. pp. 413–415. doi:10.1016/b978-012589762-4/50113-4. ISBN 978-0-12-589762-4.
- ^ "GE Healthcare". AdisInsight. 21 October 2021. Retrieved 28 August 2024.
- ^ Cite error: The named reference
Elks2014was invoked but never defined (see the help page).
Previous Page Next Page
